ArticleCureus2026
From Cost to Value: A Comparative Analysis of Medical and Surgical Management of Inflammatory Bowel Disease in a Public Referral Hospital in Mexico.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveInflammatory bowel disease (IBD) represents a growing clinical and economic challenge for healthcare systems, particularly in settings that provide free access to specialised care. Advances in medical therapy have modified disease outcomes but have also reshaped healthcare expenditure, while surgical management continues to represent high-impact cost events. Integrated analyses comparing medical and surgical costs from the perspective of public healthcare systems remain scarce in Latin America. This study aims to compare the economic burden of medical versus surgical-hospital management in patients with IBD by quantifying cumulative direct costs over 12 months from an institutional perspective using real-world data. PATIENTS AND
methodsA retrospective observational study using real-world data was conducted at the Inflammatory Bowel Disease Clinic of the Coloproctology Service, Hospital General de México "Dr. Eduardo Liceaga," a tertiary-level public referral hospital in Mexico City. A total of 118 patients (100%) with confirmed IBD managed over 12 months were included. Patients were categorized according to medical or surgical-hospital management. Direct costs related to pharmacological treatment, hospitalization, and surgical care were quantified from an institutional perspective and analyzed descriptively.
resultsAmong the 118 patients included (100%), 95 (80.5%) had ulcerative colitis and 23 (19.5%) had Crohn's disease. Medical management was required in 91 patients (77.1%), including advanced therapies in 27 (22.9%). Surgical-hospital management was necessary in 24 patients (20.3%). The cumulative annual cost of medical management for the cohort was Mexican peso (MXN) 16.4 million. In contrast, surgical-hospital management generated a total accumulated cost of MXN 15.0 million, despite involving a substantially smaller proportion of patients. Overall, approximately 95% of direct healthcare costs were absorbed by the public institution within a free-access care model.
conclusionsIn a public referral hospital, the economic burden of IBD reflects both sustained pharmacological investment and high-impact surgical events. The comparable magnitude of cumulative medical and surgical expenditures underscores the need to interpret healthcare costs in relation to clinical trajectories rather than patient volume alone, supporting value-oriented strategies to optimize resource allocation in publicly funded healthcare systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.